Eli Lilly & Co will invest $3 billion in China over the next decade to expand local production, with a focus on weight loss as the US drugmaker looks to cement its dominance in the booming obesity ...

Twelve months ago, drugmakers came roaring into 2025, fueled by a massive year of growth that peaked in the fourth quarter of 2024. Now, the momentum has dissipated, and most companies are bracing for ...

Hims & Hers Health (HIMS) has made a major change in its PR function with the hiring of Kathryn Beiser, who has served Lilly (LLY) as the weight loss drugmaker’s chief communications officer for five ...

SHANGHAI, March 11 (Reuters) - Eli Lilly (LLY.N), opens new tab plans to invest $3 billion in China over the next decade, which will help build production capacity for its experimental ‌type-2 ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

March 9 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday a small number of basic Medicare drug plans may not follow the $50 per month ‌cap on out-of-pocket costs for its weight-loss drugs, ...

Add Yahoo as a preferred source to see more of our stories on Google. A screen displays the logo and trading information for Eli Lilly and Company on the floor at the New York Stock Exchange (NYSE) in ...

Wall Street is enamored of pharmaceutical giant Eli Lilly and its GLP-1 products right now. This pharma peer has a a more modest P/E, more attractive yield, and a solid payout ratio. Eli Lilly was ...

Eli Lilly is a market darling at the moment because of its industry-leading GLP-1 drugs. The stock looks priced for perfection despite a well-known drug cycle. That's good news, but investors are well ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...